434 articles – 313 Notices  [english version]
Fiche concise
Antidepressant use before and after the diagnosis of type 2 diabetes: a longitudinal modeling study.
Kivimäki M., Tabák A., Lawlor D. A., Batty G. D., Singh-Manoux A., Jokela M., Virtanen M., Salo P., Oksanen T., Pentti J. et al
Diabetes Care 33, 7 (2010) 1471-6 - http://www.hal.inserm.fr/inserm-00482646
 (20368411) 
Antidepressant use before and after the diagnosis of type 2 diabetes: a longitudinal modeling study.
Mika Kivimäki () 1, 2, 3, Adam Tabák4, Debbie Lawlor5, G David Batty6, 7, Archana Singh-Manoux2, 8, Markus Jokela9, Marianna Virtanen3, Paula Salo3, Tuula Oksanen3, Jaana Pentti3, Daniel Witte10, Jussi Vahtera1, 2
1 :  Turku University Hospital
University of Turku – Turku University Hospital
Finlande
2 :  Department of Epidemiology and Public Health
http://www.ucl.ac.uk/epidemiology/staff/singh-manoux.htm
University College of London (UCL)
1-19 Torrington Place London WC1E 6BT
Royaume-Uni
3 :  Unit of Excellence for Psychosocial Factors
Finnish Institute of Occupational Health
Lemminkäisenkatu 14-18 B, FI-20520 Turku
Finlande
4 :  1st Department of Medicine
Semmelweis University Faculty of Medicine
Hongrie
5 :  MRC Centre for Causal Analyses in Translational Epidemiology
University of Bristol
Royaume-Uni
6 :  Social & Public Health Sciences Unit
MRC – University of Glasgow
Royaume-Uni
7 :  Centre for Cognitive Ageing and Cognitive Epidemiology
University of Edinburgh
Department of Psychology, Edinburgh,
Royaume-Uni
8 :  Santé publique et épidémiologie des déterminants professionnels et sociaux de la santé
http://www.u687.idf.inserm.fr/
INSERM : U687 – IFR69 – Université Paris XI - Paris Sud – Université de Versailles Saint-Quentin-en-Yvelines
Hôpital Paul Brousse 16, av Paul Vaillant Couturier 94807 VILLEJUIF
France
9 :  Department of Psychology
University of Helsinki
Finlande
10 :  Steno Diabetes Center
University of Copenhagen
A/S Niels Steensens Vej 2 DK-2820 Gentofte
Danemark
OBJECTIVE: To examine antidepressant use before and after the diagnosis of diabetes. RESEARCH DESIGN AND METHODS: This study was a longitudinal analysis of diabetic and nondiabetic groups selected from a prospective cohort study of 151,618 men and women in Finland (the Finnish Public Sector Study, 1995-2005). We analyzed the use of antidepressants in those 493 individuals who developed type 2 diabetes and their 2,450 matched nondiabetic control subjects for each year during a period covering 4 years before and 4 years after the diagnosis. For comparison, we undertook a corresponding analysis on 748 individuals who developed cancer and their 3,730 matched control subjects. RESULTS: In multilevel longitudinal models, the odds ratio for antidepressant use in those who developed diabetes was 2.00 (95% CI 1.57-2.55) times greater than that in nondiabetic subjects. The relative difference in antidepressant use between these groups was similar before and after the diabetes diagnosis except for a temporary peak in antidepressant use at the year of the diagnosis (OR 2.66 [95% CI 1.94-3.65]). In incident cancer case subjects, antidepressant use substantially increased after the cancer diagnosis, demonstrating that our analysis was sensitive for detecting long-term changes in antidepressant trajectories when they existed. CONCLUSIONS: Awareness of the diagnosis of type 2 diabetes may temporarily increase the risk of depressive symptoms. Further research is needed to determine whether more prevalent use of antidepressants noted before the diagnosis of diabetes relates to effects of depression, side effects of antidepressant use, or a common causal pathway for depression and diabetes.
Sciences du Vivant/Santé publique et épidémiologie
Anglais
1935-5548

Articles dans des revues avec comité de lecture
10.2337/dc09-2359
Diabetes Care (Diabetes Care)
Publisher American Diabetes Association
ISSN 0149-5992 (eISSN : 0149-5992)
internationale
07/2010
05/04/2010
33
7
1471-6

Depression – type 2 diabetes – risk factors.
Adult – Antidepressive Agents – Depressive Disorder – Diabetes Mellitus – Type 2 – Female – Finland – Humans – Longitudinal Studies – Male – Middle Aged – Neoplasms – Odds Ratio – Risk Factors
MK and JV are supported by the Academy of Finland. MK is additionally supported by a BUPA Foundation Specialist Research Grant, UK, the National Heart, Lung, and Blood Institute (R01HL036310) and the National Institute on Aging (R01AG034454)/NIH, USA; GDB is a Wellcome Trust Research Fellow, UK; AS-M is supported by a ‘EURYI' award from the European Science Foundation; and DAL works in a centre that receives some core funding from the UK Medical Research Council (MRC). The MRC Social and Public Health Sciences Unit receives funding from the UK MRC and the Chief Scientist Office at the Scottish Government Health Directorates. The Centre for Cognitive Ageing and Cognitive Epidemiology is supported by the Biotechnology and Biological Sciences Research Council, the Engineering and Physical Sciences Research Council, the Economic and Social Research Council, the Medical Research Council, and the University of Edinburgh as part of the cross-council Lifelong Health and Wellbeing initiative.
Liste des fichiers attachés à ce document : 
DOC
Kivimaki_Manuscript_Diabetes_Care_antidepressants_diabetes.doc(315 KB)
PDF
Kivimaki_Manuscript_Diabetes_Care_antidepressants_diabetes.pdf(273.6 KB)
inserm-00482646_edited.pdf(288.5 KB)
XHTML
index.xhtml(63.1 KB)